Zura Bio Limited
NASDAQ:ZURABiotechnology
+$0.07 today
- Market cap
- $92.96M
- Beta
- 0.03
- P/E (TTM)
- -5.5
- EPS (TTM)
- -$0.67
Volume 3.02M
Average 0.75M
ZURA Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
Zura Bio LimitedNASDAQ: ZURA
Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026
Cash & equivalents rises 32.3% from a year ago
Cash & equivalents stood at $225.59M at the end of Q1 FY2026, up 32.3% from a year earlier and up 106.2% from the prior quarter. Over 3 fiscal years it compounded at +311.8% a year.
Context
- Cash & equivalents amounted to 98.7% of total assets at the end of Q1 FY2026, down 0.2 pp from a year earlier.
- Cash & equivalents increased in 2 of the last 3 fiscal years.
What to watch
Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +32.3% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 109.41M USD
- Year-over-year change
- -38.0%
- 4-year CAGR
- +250.0%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 109.41M | -38.0% |
| FY2024 | 2024-12-31 | 176.5M | +76.8% |
| FY2023 | 2023-12-31 | 99.81M | +6269.2% |
| FY2022 | 2022-12-31 | 1.57M | +114.9% |
| FY2021 | 2022-03-31 | 729.22K | — |
Cash & Equivalents vs competitors
How ZURA compares with its peers on the latest reported figures
- ZURA's Mar 2026 cash & equivalents of $225.59M is the highest of the 11 companies compared; the peer median is $41.97M.
- Its year-over-year change of +32.3% is the 5th highest of 11, against a peer median of +14.7%.
- Cash & equivalents amounts to 98.7% of total assets for ZURA, versus a peer median of 23.6%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
ZURAZura Bio Limited | Mar 2026 | $225.59M | +32.3% | +311.8% | 98.7% |
| Mar 2026 | $211.38M | -2.6% | -16.2% | 86.1% | |
| Mar 2026 | $88.91M | +45.7% | +15.7% | 40.0% | |
| Mar 2026 | $80.89M | +50.4% | +1.8% | 59.9% | |
| Mar 2026 | $62.44M | +135.6% | +44.6% | 63.3% | |
| Mar 2026 | $47.32M | +31.9% | +21.0% | 0.0% | |
SGMTSagimet Biosciences Inc. | Mar 2026 | $36.63M | -43.4% | +505.2% | 34.0% |
| Mar 2026 | $34.93M | -42.0% | -9.8% | 11.1% | |
| Mar 2026 | $31.12M | +32.9% | +3.7% | 13.2% | |
| Mar 2026 | $14.63M | -56.0% | -52.4% | 8.2% | |
| Mar 2026 | $7.24M | -43.3% | -55.9% | 11.3% | |
| Peer median (excluding ZURA) | $41.97M | +14.7% | +2.8% | 23.6% | |
Competitors are the stored peer set for ZURA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Zura Bio Limited
NASDAQ:ZURA
Intrinsic Alpha fair value
Locked
Current Price
$0.97
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.